AdarX Pharmaceuticals Inc., a late-stage gene therapy research and development company, officially announced an increase in the initial public offering price and successfully raised US$446.3 million. The sale was ultimately priced at the top of its original market-guidance range of $15 to $17 — or $17 per share.

AdarX Pharmaceuticals Inc., a late-stage gene therapy research and development company, officially announced an increase in the initial public offering price and successfully raised US$446.3 million. The sale was ultimately priced at the top of its original market-guidance range of $15 to $17 — or $17 per share.